
Obesity Week 2026: Novo's CagriSema 1.7mg/1.7mg shows LESS weight loss than 1.0mg/1.0mg with 66% nausea rate & 32% vomit rate in REDEFINE-9 trial
CagriSema is really the drug that keeps on giving. After disappointing investors with the nuclear bomb results from REDEFINE-1, the stock has been in a 60% decline since then. Then the absolute cinema results from REDEFINE-4 and REIMAGINE-4 put this drug 6 feet under as Novo themselves literally proved that Mounjaro/Zepbound was better than their own drug in a head-to-head. Their own trial proved their competitor was better. Incredible. Text books will be written about these trials... Well today at Obesity Week, they expanded on the results from REDEFINE-9 where once again, it's a comedy of errors. Top line results from this trial was already released, but they BURIED the 1.7mg/1.7mg results in the fine print. Why? Well, because upping the dose gave LESS weight loss. You literally can't make this shit up... And it gets better, for the 1.7mg/1.7mg dose nausea occurred in 66% of patients and vomiting 32%!!! Even if you placebo adjust those numbers it's 40% nausea and 25% vomiting. The 1.









